T Tatar1, D Kilic, M Ozkan, A Hatipoglu, S Aslamaci.
Abstract
OBJECTIVE: Chylothorax is a rare complication of congenital cardiac surgery that can seriously impair the postoperative course unless treated properly. We present our treatment protocol and results with octreotide, a somatostatin analogue, in cases of chylothorax following congenital heart surgery.
MATERIAL AND METHODS: Between March 2006 and December 2009, 12 patients were treated for chylothorax following congenital cardiac surgery. Patients consisted of five females and seven males, with a mean age of 16.6 months (7 days - 36 months). Octreotide was administrated as a continuous intravenous infusion with a dosage of 4-10 µg/kg/h.
RESULTS: Chylothorax was successfully resolved in an average of 10.3 days (7-14 days) with octreotide infusion and a strict oral diet containing medium-chain triglycerides. At a mean follow-up of 9.4 months (1-35), all patients are doing well, without any recurrence of chylothorax.
CONCLUSION: Octreotide, a long-acting somatostatin analog, is an effective and safe agent for the treatment of postoperative chylothorax and warrants further investigation in a larger series with a greater number of patients. © Georg Thieme Verlag KG Stuttgart · New York.
OBJECTIVE: Chylothorax is a rare complication of congenital cardiac surgery that can seriously impair the postoperative course unless treated properly. We present our treatment protocol and results with octreotide, a somatostatin analogue, in cases of chylothorax following congenital heart surgery.
MATERIAL AND METHODS: Between March 2006 and December 2009, 12 patients were treated for chylothorax following congenital cardiac surgery. Patients consisted of five females and seven males, with a mean age of 16.6 months (7 days - 36 months). Octreotide was administrated as a continuous intravenous infusion with a dosage of 4-10 µg/kg/h.
RESULTS: Chylothorax was successfully resolved in an average of 10.3 days (7-14 days) with octreotide infusion and a strict oral diet containing medium-chain triglycerides. At a mean follow-up of 9.4 months (1-35), all patients are doing well, without any recurrence of chylothorax.
CONCLUSION: Octreotide, a long-acting somatostatin analog, is an effective and safe agent for the treatment of postoperative chylothorax and warrants further investigation in a larger series with a greater number of patients. © Georg Thieme Verlag KG Stuttgart · New York.
Entities:
Mesh：
Substances：
Year: 2011
PMID： 21394709 DOI： 10.1055/s-0030-1250296
Source DB: PubMed Journal: Thorac Cardiovasc Surg ISSN： 0171-6425 Impact factor: 1.827